Clinical significance of Tim-3<sup>+</sup> TILs in patients with NSCLC.
收藏NIAID Data Ecosystem2026-03-07 收录
数据链接：
官方服务：
资源简介：
Clinical significance of Tim-3+ TILs in patients with NSCLC.
应用场景：
创建时间：
2015-12-02
相关数据集
Transcriptome analysis of tumor infiltrating NK and T cells in CT26-bearing BALB/C mice
CT26 tumors were implanted subcutaneously into syngeneic BALB/C mice and allowed to grow for 15-25 days. Tumors were collected, mechanically dissociated, and immune cells enriched using Percoll gradie
NIAID Data Ecosystem60
Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. Omics study of SCLC
Small cell lung cancer (SCLC) is highly invasive and lethal. Genomic studies are beginning to characterize its genetic determinants and heterogeneity. We performed RNA-Seq and whoe exome sequencing (W
NIAID Data Ecosystem30
Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-b
NIAID Data Ecosystem10
Table_2_Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.docx
BackgroundThe combination of immune checkpoint inhibitors (ICIs) and chemotherapy is known to improve overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). ICIs have
NIAID Data Ecosystem40
DataSheet_1_Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.docx
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy
NIAID Data Ecosystem20
